Optibiotix Health Share Discussion Threads

[goliard] 11/8/2020 07:29

That's easy. It's been a few days since the last one!

[rayrac] 11/8/2020 07:28

Come on manc, give us a reason for the release of that rns today?

[rayrac] 11/8/2020 07:24

I presume so. Same old....

[kreature] 11/8/2020 07:20

‘ The next stage of its strategy is to grow sales with existing partners, extend territories and applications, and continue to sign up new partners’

and do another placing ? and make a profit ? Improve margins ?

[rayrac] 11/8/2020 07:19

Same old same old! Why that ‘news’ warranted an rns, I cannot imagine. Desperation driving it?

Same numbers for bp and cholesterol..which means they are not high enough...5.1 bp and 13.9 cholesterol. Nothing changed?

[kreature] 11/8/2020 07:08

‘ a number of customers have reported reduction’

What number is that ?

[slartybartfaster] 10/8/2020 21:12

Another hat tip to elrico for 4D.

[manc10] 10/8/2020 20:55

looks like the microbiome is the place to be

[manc10] 10/8/2020 20:53

Local startup Seres Therapeutics is poised to be one of the first biotechs to prove bacteria can treat disease, thanks to clinical trial results released Monday.

Seres Therapeutics’ (Nasdaq: MCRB) stock price shot up more than 400% on the Monday morning news that its lead drug candidate, SER-109, succeeded in a late-stage clinical trial. The biotech will now head to the FDA for approval.

“This is a catalyst to demonstrate that the microbiome has emerged from an emerging treatment modality to one that is here now,” CEO Eric Shaff told the Business Journal earlier this year.

Subjects that received the oral drug experienced a 30% reduction in the recurrence of the gastrointestinal disease C. difficile infection. The bacterial disease strikes nearly 500,000 Americans each year and can be particularly dangerous for seniors, according to the CDC.

Seres has been through ups and downs with its lead drug, which failed an earlier clinical trial. The Cambridge-based company attributed the stumble to some participants having been misdiagnosed and others not having received a large enough dose of SER-109.

The drug is designed as an alternative to fecal transplantation, rebalancing the types of bacteria in the gut and thereby preventing the recurrence of C. diff, which is common after treatment with antibiotics.

Seres is one of the most advanced players in the microbiome field.

Just 11% of the subjects in Seres’ Phase 3 trial experienced a recurrence of C.Diff, compared to 41% of the placebo subjects.

In all, the results “substantially exceeded” what the FDA wanted to see in order to approve the drug, according to Seres.

Seres is lucky to be able to present its clinical trial results on time, Shaff has said. The study was already 95% enrolled when the Covid-19 pandemic started, forcing many companies to halt testing. Seres is still evaluating the impact on another clinical trial for an ulcerative colitis treatment.


RECOMMENDED
COMMERCIAL REAL ESTATE
Fort Point, Seaport building projects get design OK

COMMERCIAL REAL ESTATE
Five things you need to know today, and the humor in renderings

RESIDENTIAL REAL ESTATE
'If you've seen it, I don't want it': Dr. Kiran Patel's palatial Carrollwood compound, with eye-catching designs at every turn, inches toward completion (Photos)


The biotech could also benefit from the commercial revenue — it currently has roughly enough funding to finance its operations into the second quarter of 2021.

[manc10] 10/8/2020 20:53

Local startup Seres Therapeutics is poised to be one of the first biotechs to prove bacteria can treat disease, thanks to clinical trial results released Monday.

Seres Therapeutics’ (Nasdaq: MCRB) stock price shot up more than 400% on the Monday morning news that its lead drug candidate, SER-109, succeeded in a late-stage clinical trial. The biotech will now head to the FDA for approval.

“This is a catalyst to demonstrate that the microbiome has emerged from an emerging treatment modality to one that is here now,” CEO Eric Shaff told the Business Journal earlier this year.

Subjects that received the oral drug experienced a 30% reduction in the recurrence of the gastrointestinal disease C. difficile infection. The bacterial disease strikes nearly 500,000 Americans each year and can be particularly dangerous for seniors, according to the CDC.

Seres has been through ups and downs with its lead drug, which failed an earlier clinical trial. The Cambridge-based company attributed the stumble to some participants having been misdiagnosed and others not having received a large enough dose of SER-109.

The drug is designed as an alternative to fecal transplantation, rebalancing the types of bacteria in the gut and thereby preventing the recurrence of C. diff, which is common after treatment with antibiotics.

Seres is one of the most advanced players in the microbiome field.

Just 11% of the subjects in Seres’ Phase 3 trial experienced a recurrence of C.Diff, compared to 41% of the placebo subjects.

In all, the results “substantially exceeded” what the FDA wanted to see in order to approve the drug, according to Seres.

Seres is lucky to be able to present its clinical trial results on time, Shaff has said. The study was already 95% enrolled when the Covid-19 pandemic started, forcing many companies to halt testing. Seres is still evaluating the impact on another clinical trial for an ulcerative colitis treatment.


RECOMMENDED
COMMERCIAL REAL ESTATE
Fort Point, Seaport building projects get design OK

COMMERCIAL REAL ESTATE
Five things you need to know today, and the humor in renderings

RESIDENTIAL REAL ESTATE
'If you've seen it, I don't want it': Dr. Kiran Patel's palatial Carrollwood compound, with eye-catching designs at every turn, inches toward completion (Photos)


The biotech could also benefit from the commercial revenue — it currently has roughly enough funding to finance its operations into the second quarter of 2021.

[rayrac] 10/8/2020 19:53

Could be a nightmare world?👉998;👹⛷

[rayrac] 10/8/2020 16:24

Still living in a dream world on the coin thread.